Deltec Asset Management LLC Takes Position in Osiris Therapeutics, Inc. (OSIR)

Deltec Asset Management LLC acquired a new position in shares of Osiris Therapeutics, Inc. (OTCMKTS:OSIR) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 50,000 shares of the biotechnology company’s stock, valued at approximately $555,000. Deltec Asset Management LLC owned about 0.14% of Osiris Therapeutics at the end of the most recent quarter.

Separately, CAPROCK Group Inc. purchased a new stake in Osiris Therapeutics in the third quarter valued at $111,000. 0.28% of the stock is currently owned by hedge funds and other institutional investors.

Shares of OSIR opened at $10.25 on Friday. Osiris Therapeutics, Inc. has a 1-year low of $4.20 and a 1-year high of $13.70.

Osiris Therapeutics (OTCMKTS:OSIR) last announced its quarterly earnings results on Wednesday, August 8th. The biotechnology company reported $0.07 earnings per share for the quarter. The company had revenue of $33.88 million during the quarter.

Separately, TheStreet raised shares of Osiris Therapeutics from a “d+” rating to a “c-” rating in a research report on Wednesday, October 3rd.

Osiris Therapeutics Company Profile

Osiris Therapeutics, Inc researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints.

Featured Article: Intrinsic Value and Stock Selection

Receive News & Ratings for Osiris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osiris Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply